<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448628</url>
  </required_header>
  <id_info>
    <org_study_id>CS3150-A-J206</org_study_id>
    <nct_id>NCT02448628</nct_id>
  </id_info>
  <brief_title>A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment</brief_title>
  <official_title>A Multi-center, Open Label, Dose Titration, Exploratory Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, open label, dose titration, exploratory study to evaluate
      efficacy and safety of CS-3150 in Japanese hypertensive patients with moderate renal
      impairment. Primary endpoint is change from baseline in sitting systolic and diastolic blood
      pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in sitting systolic and diastolic blood pressure</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in UACR</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
    <description>Urine Albumin Creatinine Ratio (UACR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum potassium</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>CS-3150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-3150 1.25 to 5.0 mg , orally, once daily after breakfast for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-3150</intervention_name>
    <arm_group_label>CS-3150</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women Aged 20 years or older and 80 years or younger at informed consent

          -  Subjects with hypertension (Sitting systolic blood pressure SBP &gt;= 140 mmHg and &lt; 180
             mmHg, Sitting diastolic blood pressure DBP &gt;= 80 mmHg and &lt; 110 mmHg)

          -  estimated glomerular filtration rate eGFR &gt;= 30 mL/min/1.73 m2 and &lt; 60 mL/min/1.73 m2

        Exclusion Criteria:

          -  Secondary hypertension or malignant hypertension

          -  Diabetes mellitus with albuminuria

          -  Serum potassium level &lt; 3.5 or &gt;= 5.1 mEq/L

          -  Subjects under Insulin treatment

          -  Subjects under or pre-planned for hemodialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2015</study_first_submitted>
  <study_first_submitted_qc>May 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>April 6, 2016</last_update_submitted>
  <last_update_submitted_qc>April 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>moderate renal impairment</keyword>
  <keyword>mineralocorticoid receptor antagonist</keyword>
  <keyword>CS-3150</keyword>
  <keyword>Japanese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

